No new data on radium-223 (Alpharadin) was presented at the European Association of Urology 2012 Congress in Paris today.
Dr Chris Parker presented a poster with similar data to his oral presentation on Alpharadin at the recent ASCO GU meeting. The phase III ALSYMPCA trial results were first presented at ECCO/ESMO in Stockholm last year.
However, one of things I did learn at EAU12 was that Bayer have opened an Expanded Access Program for Alpharadin, that allows eligble advanced prostate cancer patients access to this radiopharmaceutical pending regulatory approval.
I was told by a Bayer representative that a license is required but that they are now approving sites so that they can administer Alpharadin in the United States pending regulatory approval.
Further information is available about the trial (NCT01516762), and inclusion/exclusion criteria are available on the clinicaltrials.gov website. This is good news for advanced prostate cancer patients.